Physician profile
Deval D Joshi
NPI 1114116142
$12,612.30
in general payments reported to CMS, 2019-2025
36 companies · $1,920 in 2025
The $1,920 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,009 · 2020: $187 · 2021: $1,161 · 2022: $1,464 · 2023: $4,022 · 2024: $1,849 · 2025: $1,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,578 · Travel and Lodging: $1,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,578.03 |
| Travel and Lodging | $1,213.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,832.07 | 2019-2025 | Lensx, Clareon, Clareon Panoptix Pro |
| Genentech USA, INC. | $895.21 | 2019-2025 | Vabysmo, Susvimo |
| Regeneron Healthcare Solutions, INC. | $833.55 | 2019-2025 | Eylea Hd, Eylea |
| Dutch Ophthalmic, USA | $799.53 | 2023-2025 | Tissueblue, Eva, Combined Machine |
| New World Medical,INC. | $643.86 | 2023-2025 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Harrow Eye, LLC | $606.57 | 2024-2025 | Iheezo, Vevye, Triesence |
| Horizon Therapeutics Plc | $589.60 | 2021-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $561.51 | 2019 | |
| Mallinckrodt Hospital Products INC. | $497.46 | 2022-2024 | Acthar |
| Abbvie INC. | $459.02 | 2022-2025 | |
| Rayner Intraocular Lenses Limited | $442.33 | 2022-2024 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Allergan, INC. | $433.23 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $420.35 | 2023-2025 | Syfovre |
| Kala Pharmaceuticals, INC. | $394.58 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $340.09 | 2023-2025 | Quatera 700 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $300.07 | 2024-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Johnson & Johnson Surgical Vision, INC. | $288.95 | 2021-2025 | Tecnis Iol, Tecnis Iol |
| Astellas Pharma US INC | $262.02 | 2023-2025 | Izervay |
| Aerie Pharmaceuticals, INC. | $246.36 | 2019-2021 | |
| Omeros Corporation | $234.27 | 2019-2021 | |
| Biotissue Holdings INC. | $202.62 | 2021-2025 | |
| Notal Vision, INC. | $187.85 | 2022 | |
| Ocular Therapeutix, INC. | $142.20 | 2023 | Dextenza |
| Sun Pharmaceutical Industries INC. | $136.58 | 2019-2022 | |
| Sight Sciences, INC. | $122.07 | 2019 | |
| Eyevance Pharmaceuticals LLC | $109.10 | 2022 | |
| Spark Therapeutics, INC. | $105.68 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $105.33 | 2024 | Xdemvy |
| Dompe US, INC. | $102.57 | 2021 | |
| Bausch & Lomb Americas INC. | $98.75 | 2022-2025 | Stellaris, Miebo, Vyzulta |
| Coherus Oncology, INC. | $72.96 | 2022-2023 | |
| Eyepoint US, INC. | $72.48 | 2019-2022 | |
| Alimera Sciences, INC. | $42.49 | 2022 | |
| Topcon Healthcare, INC. | $15.56 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.43 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deval Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.